Skip to main content
Neurology® Neuroimmunology & Neuroinflammation logoLink to Neurology® Neuroimmunology & Neuroinflammation
. 2021 Apr 19;8(4):e1013. doi: 10.1212/NXI.0000000000001013

Discontinuation of Immunosuppressive Therapy in Patients With Neuromyelitis Optica Spectrum Disorder With Aquaporin-4 Antibodies

PMCID: PMC8192055  PMID: 33875580

In the article “Discontinuation of Immunosuppressive Therapy in Patients With Neuromyelitis Optica Spectrum Disorder With Aquaporin-4 Antibodies” by S.-H. Kim et al,1 Su-Hyun Kim's contributions listed in the appendix should be “Drafting/revision of the manuscript for content, major role in the acquisition of data, study concept or design, and analysis or interpretation of data.” The publisher regrets the error.

Reference

  • 1.Kim S-H, Jang H, Park NY, et al. . Discontinuation of immunosuppressive therapy in patients with neuromyelitis optica spectrum disorder with aquaporin-4 antibodies. Neurol Neuroimmunol Neuroinflamm 2021;8:e947. doi: 10.1212/NXI.0000000000000947. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Neurology® Neuroimmunology & Neuroinflammation are provided here courtesy of American Academy of Neurology

RESOURCES